Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by collection
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by collection
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Archive
Volume 8, Issue Suppl 3
291 Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors
Email alerts
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts
PDF
XML
Regular and young investigator award abstracts
Clinical trials completed
291 Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors
Online download statistics by month:
Online download statistics by month: November 2020 to May 2022
Abstract
Full
Pdf
Nov 2020
187
0
29
Dec 2020
38
0
6
Jan 2021
48
0
13
Feb 2021
104
0
18
Mar 2021
190
0
28
Apr 2021
204
0
24
May 2021
83
0
21
Jun 2021
0
0
19
Jul 2021
0
0
13
Aug 2021
0
0
11
Sep 2021
0
0
12
Oct 2021
94
0
24
Nov 2021
183
0
28
Dec 2021
122
0
13
Jan 2022
90
0
2
Feb 2022
112
0
35
Mar 2022
130
0
15
Apr 2022
114
0
13
May 2022
108
0
13
Total
1807
0
337
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?